Treace Medical Concepts, Inc. (TMCI) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East uncertainty lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Plug Power COO resigns to join another company
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Wall Street ends down as oil prices, Treasury yields rise
Treace Medical Concepts Reports Second Quarter 2022 Financial Results
August 9, 2022 4:05 PM EDTPONTE VEDRA, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (Treace or the Company) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the second quarter ended June 30, 2022.
Recent Highlights:
Revenue of $30.0 million in the second quarter 2022, a 45% increase over the same period last year. Blended average revenue per case increased 5% to over $5,700 from the same period last... More